Teva Pharmaceutical (TEVA) Updates Court Ruling to Market Generic Seroquel
More News related to AZN
- Bristol-Myers Squibb and AstraZeneca to Hold Investor Teleconference to Discuss EASD Highlights
- Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu
- AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
- Abbott (ABT) and AstraZeneca (AZN) to Co-Promote CRESTOR(R)
- Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
More News related to TEVA
- Teva (TEVA) and Barr (BRL) Receive FTC Second Request Regarding Pending Acqusition
- Teva and Barr Receive FTC Request for Additional Information
- Teva and Barr Receive FTC Request for Additional Information
- Analyst Reports for Electronic Arts Inc., Teva Pharmaceutical Industries Limited, ACADIA Pharmaceuticals Inc., and Sport Supply Group Inc.
- Group Acquires IVAX Diagnostics (IVD) Shares From Teva Pharmaceutical (TEVA) for $14 Million
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. District Court for the District of New Jersey has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca's (NYSE: AZN) Seroquel (Quetiapine) Tablets. The Court granted summary judgment in AstraZeneca's favor on the issue of no inequitable conduct with regard to AstraZeneca's U.S. Patent No. 4,879,288. Teva plans to appeal this decision.
Teva Pharmaceutical Industries Ltd. is a Global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories. [SM]
Related Categories
FDAStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
